Diuretic Tolerance to Repeated-Dose Furosemide in Infants Born Very Preterm with Bronchopulmonary Dysplasia

Nicolas A Bamat1, Matthew Huber2, Justine Shults3

  • 1Division of Neonatology, Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

The Journal of Pediatrics
|November 2, 2023
PubMed

Insights

Infants with bronchopulmonary dysplasia (BPD) develop rapid furosemide diuretic tolerance with repeated dosing. Thiazide co-administration did not alter this tolerance, suggesting a need for adjusted dosing strategies in BPD management.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pharmacology
  • Respiratory Medicine

Background:

  • Bronchopulmonary dysplasia (BPD) is a chronic lung disease in preterm infants.
  • Diuretic therapy, often with furosemide, is commonly used in BPD management.
  • Understanding diuretic tolerance is crucial for optimizing treatment.

Purpose of the Study:

  • To evaluate the development and timing of furosemide diuretic tolerance in infants with BPD.
  • To investigate whether thiazide co-administration impacts furosemide tolerance.

Main Methods:

  • Retrospective cohort study of very preterm infants with BPD.
  • Assessed net fluid balance as a measure of diuresis before and after 72-hour furosemide exposure.
  • Utilized general linear models to analyze fluid balance changes over time, including thiazide interaction.

Main Results:

  • Infants with BPD demonstrated rapid development of furosemide tolerance, with diuretic response decreasing significantly by the third 24-hour interval.
  • Thiazide co-administration did not influence the development of furosemide tolerance.
  • Infant weight decreased initially after furosemide but subsequently increased.

Conclusions:

  • Repeated-dose furosemide leads to quick diuretic tolerance in infants with BPD.
  • Clinicians should consider this tolerance when managing fluid balance and therapeutic goals.
  • Further research is needed to establish optimal furosemide dosing regimens for infants with BPD.
Abstract

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
96
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
300
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15